These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2126737)

  • 1. Pharmacokinetics and endocrine effects of slow release formulations of LHRH analogues.
    Sandow J; Stoeckemann K; Jerabek-Sandow G
    J Steroid Biochem Mol Biol; 1990 Dec; 37(6):925-31. PubMed ID: 2126737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the luteinizing-hormone-releasing hormone (LHRH) antagonist ramorelix (hoe013) and the LHRH agonist buserelin on dimethylbenz[]anthracene-induced mammary carcinoma: studies with slow-release formulations.
    Stoeckemann K; Sandow J
    J Cancer Res Clin Oncol; 1993; 119(8):457-62. PubMed ID: 8509436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum concentration and urinary excretion of the luteinizing hormone-releasing hormone agonist buserelin in patients with endometriosis.
    Kiesel L; Sandow J; Bertges K; Jerabek-Sandow G; Trabant H; Runnebaum B
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1167-73. PubMed ID: 2498387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-acting gonadotrophin releasing hormone agonist implant causes variable duration of suppression of ovarian steroid and inhibin secretion.
    Fraser HM; Haining R; Cowen GM; Sandow J; Smith KB; Smith SK
    Clin Endocrinol (Oxf); 1992 Jan; 36(1):97-104. PubMed ID: 1559303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and endocrine effects of the LHR analogue buserelin after subcutaneous implantation of a slow release preparation in prostatic cancer patients.
    Blom JH; Hirdes WH; Schröder FH; de Jong FH; Kwekkeboom DJ; van't Veen AJ; Sandow J; Krauss B
    Urol Res; 1989; 17(1):43-6. PubMed ID: 2493705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relation between pharmacokinetics and endocrine effects of buserelin implants in patients with mastalgia.
    Klijn JG; van Geel B; de Jong FH; Sandow J; Krauss B
    Clin Endocrinol (Oxf); 1991 Apr; 34(4):253-8. PubMed ID: 1908753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pituitary-testicular function is suppressed by an LHRH antagonist but not by an LHRH agonist in the marmoset monkey.
    Lunn SF; Dixson AF; Sandow J; Fraser HM
    J Endocrinol; 1990 May; 125(2):233-9. PubMed ID: 2165119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of LH and FSH secretion by LH-releasing hormone, by the LH-releasing hormone analogue, buserelin, and by combined treatment with LH-releasing hormone and oestradiol benzoate.
    Schuiling GA; Pols-Valkhof N; van der Schaaf-Verdonk GC; Koiter TR
    J Endocrinol; 1984 Dec; 103(3):301-9. PubMed ID: 6438265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical appreciation of LHRH analogue formulations.
    Lemay A
    Horm Res; 1989; 32 Suppl 1():93-101; discussion 102. PubMed ID: 2533161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contraception with an LHRH agonist: effect on gonadotrophin and steroid secretion patterns.
    Kuhl H; Jung C; Taubert HD
    Clin Endocrinol (Oxf); 1984 Aug; 21(2):179-88. PubMed ID: 6432376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological studies on androgen suppression in therapy of prostate carcinoma.
    Sandow J; von Rechenberg W; Engelbart K
    Am J Clin Oncol; 1988; 11 Suppl 1():S6-10. PubMed ID: 3291602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.
    Ahmann FR; Citrin DL; deHaan HA; Guinan P; Jordan VC; Kreis W; Scott M; Trump DL
    J Clin Oncol; 1987 Jun; 5(6):912-7. PubMed ID: 2953870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of the gonadotropin-releasing hormone agonist buserelin after injection of a slow-release preparation in normal men.
    Behre HM; Sandow J; Nieschlag E
    Arzneimittelforschung; 1992 Jan; 42(1):80-4. PubMed ID: 1586387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duration of testosterone suppression after a 9.45 mg implant of the GnRH-analogue buserelin in patients with localised carcinoma of the prostate a 12-month follow-up study.
    Pettersson B; Varenhorst E; Petas A; Sandow J
    Eur Urol; 2006 Sep; 50(3):483-9. PubMed ID: 16626856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prolonged action of the LHRH agonist buserelin (HOE 766) may be due to prolonged binding to the LHRH receptor.
    Koiter TR; Denef C; Andries M; Moes H; Schuiling GA
    Life Sci; 1986 Aug; 39(5):443-52. PubMed ID: 3016440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-monthly depot gonadotropin releasing hormone agonist (buserelin) for treatment of prostatic cancer.
    Waxman JH; Sandow J; Abel P; Farah N; O'Donoghue EP; Fleming J; Cox J; Sikora K; Williams G
    Acta Endocrinol (Copenh); 1989 Mar; 120(3):315-8. PubMed ID: 2494825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of LHRH agonists and antagonists in male and female bonnet monkeys (Macaca radiata).
    Jagannadha Rao A; Chakraborti R; Kotagi SG; Ravindranath N; Moudgal NR
    J Steroid Biochem; 1985 Nov; 23(5B):807-9. PubMed ID: 3935865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparisons of the potential utility of LHRH agonists and antagonists for fertility control.
    Vickery BH
    J Steroid Biochem; 1985 Nov; 23(5B):779-91. PubMed ID: 3001420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Goserelin acetate implant: a depot luteinizing hormone-releasing hormone analog for advanced prostate cancer.
    Goldspiel BR; Kohler DR
    DICP; 1991; 25(7-8):796-804. PubMed ID: 1835221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The first clinical use of depot buserelin for advanced prostatic carcinoma.
    Waxman JH; Sandow J; Man A; Barnett MJ; Hendry WF; Besser GM; Oliver RT; Magill PJ
    Cancer Chemother Pharmacol; 1986; 18(2):174-5. PubMed ID: 3098445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.